ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics SA (NYSE: ADCT), a leader in antibody drug conjugates (ADCs), has granted options to purchase 17,900 common shares to four new employees on September 3, 2024. These grants, approved by the Compensation Committee, are part of the company's Inducement Plan to attract and retain top talent. The options will vest over four years, with 25% vesting on the first anniversary and 1/48th vesting monthly thereafter, contingent on continued employment. This move aligns with NYSE's Listed Company Manual Rule 303A.08, demonstrating ADC Therapeutics' commitment to incentivizing high performance and long-term success.
ADC Therapeutics SA (NYSE: ADCT), leader nei conjugati di farmaci a base di anticorpi (ADCs), ha concesso opzioni per l'acquisto di 17.900 azioni ordinarie a quattro nuovi dipendenti il 3 settembre 2024. Questi conferimenti, approvati dal Comitato per la Retribuzione, fanno parte del Piano di Induzione dell'azienda per attrarre e trattenere i migliori talenti. Le opzioni matureranno in quattro anni, con il 25% che matura al primo anniversario e 1/48 che matura mensilmente da quel momento in poi, a condizione di un impiego continuativo. Questa mossa è in linea con la Regola 303A.08 del Manuale delle Aziende Nazionali quotate, dimostrando l'impegno di ADC Therapeutics a incentivare l'alta prestazione e il successo a lungo termine.
ADC Therapeutics SA (NYSE: ADCT), líder en conjugados de fármacos anticuerpos (ADCs), ha otorgado opciones para comprar 17,900 acciones ordinarias a cuatro nuevos empleados el 3 de septiembre de 2024. Estas concesiones, aprobadas por el Comité de Compensación, son parte del Plan de Inducción de la empresa para atraer y retener talento de alto nivel. Las opciones se adquirirán en un período de cuatro años, con el 25% adquiriéndose en el primer aniversario y 1/48 mensual a partir de entonces, dependiendo de la continuidad del empleo. Este movimiento se alinea con la Regla 303A.08 del Manual de Empresas Cotizadas de la NYSE, demostrando el compromiso de ADC Therapeutics con la incentivación del alto rendimiento y el éxito a largo plazo.
ADC Therapeutics SA (NYSE: ADCT)는 항체 약물 접합체(ADCs) 분야의 선두주자로, 2024년 9월 3일에 네 명의 신규 직원에게 17,900주 보통주 매입 옵션을 부여하였습니다. 이 부여는 보상위원회의 승인을 받아, 최고의 인재를 유치하고 유지하기 위한 회사의 유인 계획의 일부입니다. 옵션은 4년에 걸쳐 확정된다, 첫 해가 지난 후 25%가 확정되고, 그 이후 1/48이 매월 확정되며 계속 고용된 경우에 해당합니다. 이 조치는 NYSE의 상장 회사 매뉴얼 규칙 303A.08과 일치하며, ADC Therapeutics가 높은 성과와 장기적인 성공을 유도하기 위한 의지를 보여줍니다.
ADC Therapeutics SA (NYSE: ADCT), un leader dans le domaine des conjugués d'anticorps (ADCs), a accordé des options d'achat de 17 900 actions ordinaires à quatre nouveaux employés le 3 septembre 2024. Ces attributions, approuvées par le Comité de Rémunération, font partie du Plan d'Induction de l'entreprise pour attirer et retenir les meilleurs talents. Les options acquiront droit sur une période de quatre ans, avec 25 % acquérant droit lors du premier anniversaire et 1/48 par mois par la suite, sous réserve d'une continuité d'emploi. Cette initiative est conforme à la règle 303A.08 du Manuel des entreprises cotées de la NYSE, démontrant l'engagement d'ADC Therapeutics à inciter à la performance élevée et au succès à long terme.
ADC Therapeutics SA (NYSE: ADCT), ein führendes Unternehmen im Bereich Antikörper-Wirkstoff-Konjugate (ADCs), hat am 3. September 2024 Optionsscheine für den Kauf von 17.900 Stammaktien an vier neue Mitarbeiter vergeben. Diese Vergaben, die vom Vergütungsausschuss genehmigt wurden, sind Teil des Werbeplans des Unternehmens, um Spitzenkräfte zu gewinnen und zu halten. Die Optionen werden über vier Jahre gesperrt, wobei 25% am ersten Jahrestag und 1/48 monatlich danach fällig werden, abhängig von einer fortgesetzten Anstellung. Diese Maßnahme steht im Einklang mit der Regel 303A.08 des Handbuchs für börsennotierte Unternehmen der NYSE und zeigt das Engagement von ADC Therapeutics, hohe Leistungen und langfristigen Erfolg zu fördern.
- Attracting new talent with stock options, potentially aligning employee interests with company success
- Compliance with NYSE rules for employee inducement grants
- Potential dilution of existing shareholders' equity due to new stock options
LAUSANNE, Switzerland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 17,900 of the Company’s common shares to four new employees on September 3, 2024 (each, a “Grant”).
The Grants were offered as material inducement to the employees’ employment. The grants were approved by the Compensation Committee of the Company’s Board of Directors pursuant to the Company’s Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grants were made in reliance on the employment inducement exemption under the NYSE’s Listed Company Manual Rule 303A.08.
The Company is issuing this press release pursuant to Rule 303A.08. The Grants shall vest and become exercisable
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland, and has operations in London and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on LinkedIn.
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “would”, “expect”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “seem”, “seek”, “future”, “continue”, or “appear” or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the expected cash runway into mid-2026 the Company’s ability to grow ZYNLONTA® revenue in the United States; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company’s or its partners’ research and development projects or clinical trials including LOTIS 5 and 7, ADCT 601 and 602 as well as early research in certain solid tumors with different targets, linkers and payloads; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company’s products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company’s indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company’s activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company’s ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the “Risk Factors” section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.
CONTACTS:
Investors
Marcy Graham
ADC Therapeutics
Marcy.Graham@adctherapeutics.com
+1 650-667-6450
Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040
FAQ
How many stock options did ADC Therapeutics (ADCT) grant to new employees on September 3, 2024?
What is the vesting schedule for the stock options granted by ADC Therapeutics (ADCT)?
Under which plan were the stock options granted by ADC Therapeutics (ADCT)?
What NYSE rule does ADC Therapeutics (ADCT) comply with for these employee grants?
